MoonLake Immunotherapeutics MLTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $220.92M+62.2% | $202.86M+79.9% | $187.22M+133% | $162.32M+210% | $136.22M+264% | ||
| $267.37M+56.6% | $244.84M+71.1% | $229.2M+111% | $200.88M+156% | $170.76M+180% | ||
| $1.08M+196% | $611K+117% | $404K+41.8% | $381K+71.7% | $365K+139% | ||
| -$257.08M-77.0% | -$227.32M-91.1% | -$210.5M-161% | -$176.16M-221% | -$145.21M-257% | ||
| -$264.29M-56.1% | -$242.22M-70.9% | -$226.97M-111% | -$199.04M-157% | -$169.32M-180% | ||
| -$267.37M-56.6% | -$244.84M-71.1% | -$229.2M-111% | -$200.88M-156% | -$170.76M-180% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.